James Finke

James Finke

UNVERIFIED PROFILE

Are you James Finke?   Register this Author

Register author
James Finke

James Finke

Publications by authors named "James Finke"

Are you James Finke?   Register this Author

62Publications

1500Reads

36Profile Views

Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8 T cells from negative regulation by local IFN-γ.

Cancer Immunol Immunother 2019 Mar 14;68(3):395-405. Epub 2018 Dec 14.

Department of Inflammation and Immunity, Cleveland Clinic, Lerner Research Institute, 9500 Euclid Avenue NE40, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-2280-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428620PMC
March 2019

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.

Br J Cancer 2016 10 25;115(8):920-928. Epub 2016 Aug 25.

Department of Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue R40, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061902PMC
October 2016

Myeloid-derived suppressor cells: The green light for myeloma immune escape.

Blood Rev 2016 09 12;30(5):341-8. Epub 2016 Apr 12.

Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2016.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411302PMC
September 2016

Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.

J Neurooncol 2015 Apr 13;122(2):293-301. Epub 2015 Jan 13.

Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, S70, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1720-6DOI Listing
April 2015

Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.

Front Oncol 2014 29;4:266. Epub 2014 Sep 29.

Department of Dermatology, University of Pittsburgh , Pittsburgh, PA , USA ; Department of Immunology, University of Pittsburgh , Pittsburgh, PA , USA ; University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178427PMC
October 2014

The role of inflammation in kidney cancer.

Adv Exp Med Biol 2014 ;816:197-234

Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-0348-0837-8_9DOI Listing
September 2014

Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.

Int J Cancer 2014 Apr 8;134(7):1695-705. Epub 2013 Oct 8.

Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28488DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947113PMC
April 2014

Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Cancer J 2013 Jul-Aug;19(4):353-64

Department of Immunology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31829da0aeDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879112PMC
February 2014

Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer.

Front Oncol 2013 15;3:49. Epub 2013 Mar 15.

Department of Internal Medicine, The Cleveland Clinic Foundation Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597982PMC
March 2013

Defining the critical hurdles in cancer immunotherapy.

Authors:
Bernard A Fox Dolores J Schendel Lisa H Butterfield Steinar Aamdal James P Allison Paolo Antonio Ascierto Michael B Atkins Jirina Bartunkova Lothar Bergmann Neil Berinstein Cristina C Bonorino Ernest Borden Jonathan L Bramson Cedrik M Britten Xuetao Cao William E Carson Alfred E Chang Dainius Characiejus A Raja Choudhury George Coukos Tanja de Gruijl Robert O Dillman Harry Dolstra Glenn Dranoff Lindy G Durrant James H Finke Jerome Galon Jared A Gollob Cécile Gouttefangeas Fabio Grizzi Michele Guida Leif Håkansson Kristen Hege Ronald B Herberman F Stephen Hodi Axel Hoos Christoph Huber Patrick Hwu Kohzoh Imai Elizabeth M Jaffee Sylvia Janetzki Carl H June Pawel Kalinski Howard L Kaufman Koji Kawakami Yutaka Kawakami Ulrich Keilholtz Samir N Khleif Rolf Kiessling Beatrix Kotlan Guido Kroemer Rejean Lapointe Hyam I Levitsky Michael T Lotze Cristina Maccalli Michele Maio Jens-Peter Marschner Michael J Mastrangelo Giuseppe Masucci Ignacio Melero Cornelius Melief William J Murphy Brad Nelson Andrea Nicolini Michael I Nishimura Kunle Odunsi Pamela S Ohashi Jill O'Donnell-Tormey Lloyd J Old Christian Ottensmeier Michael Papamichail Giorgio Parmiani Graham Pawelec Enrico Proietti Shukui Qin Robert Rees Antoni Ribas Ruggero Ridolfi Gerd Ritter Licia Rivoltini Pedro J Romero Mohamed L Salem Rik J Scheper Barbara Seliger Padmanee Sharma Hiroshi Shiku Harpreet Singh-Jasuja Wenru Song Per Thor Straten Hideaki Tahara Zhigang Tian Sjoerd H van Der Burg Paul von Hoegen Ena Wang Marij Jp Welters Hauke Winter Tara Withington Jedd D Wolchok Weihua Xiao Laurence Zitvogel Heinz Zwierzina Francesco M Marincola Thomas F Gajewski Jon M Wigginton Mary L Disis

J Transl Med 2011 Dec 14;9:214. Epub 2011 Dec 14.

Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-5876-9-214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338100PMC
December 2011

Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.

J Clin Immunol 2011 Aug 13;31(4):690-8. Epub 2011 Apr 13.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10875-011-9530-xDOI Listing
August 2011

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Int Immunopharmacol 2011 Jul 11;11(7):856-61. Epub 2011 Feb 11.

Department Immunology, NE40, Cleveland Clinic College of Medicine of CWRU, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S156757691100065
Publisher Site
http://dx.doi.org/10.1016/j.intimp.2011.01.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109226PMC
July 2011

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.

Cancer Res 2010 May 20;70(9):3526-36. Epub 2010 Apr 20.

Department of Immunology, Taussig Cancer Institute, and Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-3278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426924PMC
May 2010

Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.

Urology 2010 Feb 5;75(2):257-61. Epub 2009 Dec 5.

Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2009.09.052DOI Listing
February 2010

Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model.

J Urol 2010 Jan;183(1):333-8

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.08.110DOI Listing
January 2010

GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.

Cancer Res 2009 Apr 10;69(7):3095-104. Epub 2009 Mar 10.

Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-3776DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728031PMC
April 2009

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Clin Cancer Res 2008 Oct;14(20):6674-82

Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-5212DOI Listing
October 2008

Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.

Cancer Chemother Pharmacol 2008 Jul 2;62(2):347-54. Epub 2007 Oct 2.

Experimental Therapeutics Program, Department of Hematology and Medical Oncology/ R33, The Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0594-5DOI Listing
July 2008

Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells.

J Interferon Cytokine Res 2008 Apr;28(4):221-33

Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jir.2007.0090DOI Listing
April 2008

Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.

Crit Rev Immunol 2007 ;27(5):485-93

Department of Dermatology, University of Pittsburgh School of Medicine, PA 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1615/critrevimmunol.v27.i5.60DOI Listing
February 2008

TNF-alpha induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction.

J Immunol 2007 May;178(10):6642-52

Department of Immunology, Lerner Research Institute, Experimental Therapeutics, Taussig Cancer Center, Cleveland Clinic Foundation, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.178.10.6642DOI Listing
May 2007

GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction.

Cancer Res 2006 Jul;66(13):6816-25

Department of Immunology and Mass Spectrometry Core, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-0250DOI Listing
July 2006

Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.

Clin Genitourin Cancer 2006 Jun;5(1):50-6

Oncology and Transplantation, University of Minnesota, Minneapolis, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CGC.2006.n.017DOI Listing
June 2006

Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.

Cancer Res 2005 Jun;65(12):5428-38

Department of Neurosurgery, Brain Tumor Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-4395DOI Listing
June 2005

Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.

Clin Cancer Res 2005 Jan;11(1):226-31

Department of Immunology and Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213-1863, USA.

View Article

Download full-text PDF

Source
January 2005

Effect of renal cell carcinomas on the development of type 1 T-cell responses.

Clin Cancer Res 2004 Sep;10(18 Pt 2):6360S-6S

Department of Immunology in the Lerner Research Institute, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-050011DOI Listing
September 2004

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.

J Clin Oncol 2004 Jul;22(14):2891-900

Experimental Therapeutics Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2004.10.045
Publisher Site
http://dx.doi.org/10.1200/JCO.2004.10.045DOI Listing
July 2004

Renal carcinoma cells undergo apoptosis without oligonucleosomal DNA fragmentation.

Biochem Biophys Res Commun 2004 Jun;318(3):710-3

Department of Urology, School of Medicine, Nihon University, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2004.04.086DOI Listing
June 2004

Mechanisms of immune dysfunction in renal cell carcinoma.

Cancer Treat Res 2003 ;116:29-51

Department of Immunology, Lerner Research Institute, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/978-1-4615-0451
Web Search
http://link.springer.com/content/pdf/10.1007%2F978-1-59259-2
Web Search
http://dx.doi.org/10.1007/978-1-4615-0451-1_2DOI Listing
May 2004

Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas.

J Immunol 2004 Mar;172(6):3480-90

Department of Immunology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.172.6.3480DOI Listing
March 2004

The Bcl-2 transgene protects T cells from renal cell carcinoma-mediated apoptosis.

Clin Cancer Res 2003 Sep;9(11):4060-8

Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
September 2003

Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.

Cancer Res 2003 Aug;63(15):4481-9

Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
August 2003

Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells.

Cancer Res 2003 Apr;63(7):1676-83

Department of Immunology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
April 2003

Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.

Clin Cancer Res 2003 Apr;9(4):1354-60

Experimental Therapeutics Program, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
April 2003

Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression.

Urology 2002 Jan;59(1):9-14

Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0090-4295(01)01503-5DOI Listing
January 2002